EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Spexis AG's enterprise value is CHF10.61 Mil.
Spexis AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-11.03 Mil. Therefore, Spexis AG's EV-to-EBITDA for today is -0.96.
The historical rank and industry rank for Spexis AG's EV-to-EBITDA or its related term are showing as below:
XSWX:SPEX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.45 Med: 0.8 Max: 2.29
Current: -0.96
During the past 10 years, the highest EV-to-EBITDA of Spexis AG was 2.29. The lowest was -11.45. And the median was 0.80.
XSWX:SPEX's EV-to-EBITDA is ranked worse than 100% of 462
companies
in the Biotechnology industry
Industry Median: 9.55
vs XSWX:SPEX: -0.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-05), Spexis AG's stock price is CHF0.0542.
Spexis AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-0.250. Therefore, Spexis AG's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Spexis AG EV-to-EBITDA Historical Data
The historical data trend for Spexis AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spexis AG's EV-to-EBITDA
For the Biotechnology subindustry, Spexis AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spexis AG's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spexis AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Spexis AG's EV-to-EBITDA falls into.
Spexis AG EV-to-EBITDA Calculation
Spexis AG's EV-to-EBITDA for today is calculated as:
Spexis AG's current Enterprise Value is CHF10.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spexis AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-11.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spexis AG (XSWX:SPEX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Spexis AG's share price for today is CHF0.0542.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spexis AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-0.250.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Spexis AG's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:SPEX has been successfully added to your 